Business Standard

The obvious opportunity is biosimilars, says Biocon's Kiran Mazumdar-Shaw

A month ago, Biocon announced that its biosimilar insulin glargine trademarked as Semglee received marketing approval from the European Commission

Approval for generics drug up but US business shrinks for home firms
Premium

Pavan Lall
Biocon, which has aggressively invested in the biologics business, grew at an impressive 47 per cent in the March quarter, with the segment accounting for over a fifth of the company's revenue. A year ago biologics contributed 17.5 per cent to the biopharmaceutical firm’s revenue. The biopharmaceutical company's profit before interest and tax grew 22 per cent to Rs 1.93 billion, aided by biologics, which turned in a profit of Rs 194 million.

For Biocon, it is really biosimilars that will push the needle going ahead. Shorn of jargon, biosimilars are biological products that are highly similar to and have

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in